Recently, Insilico Medicine secured $37 million in series B funding. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture and Kaitai Capital. Our Pharma.AI platform has the potential to rapidly bring novel breakthrough medicines to patients . Eccogene is a clinical stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally. Dr. Ding and Dr. Cote-Sierra together with Prof. Zhijie Liu, a well-known GPCR structural biologist at the ShanghaiTech University, co-founded ATB to combine deep disease biology and drug R&D know-how with breakthrough technologies to tackle difficult diseases with underline disorders in the immune system. This site needs JavaScript to work properly. Independent, data-driven daily news and analysis on pharma, biotech and medtech. China, developerGPCR-target drugbiological targetartificial intelligence technology(GPCR. Linkedin Clin Lung Cancer. Yamaoka T, Ohmori T, Ohba M, Arata S, Kishino Y, Murata Y, Kusumoto S, Ishida H, Shirai T, Hirose T, Ohnishi T, Sasaki Y. Mol Cancer Ther. Disclaimer. At Recludix, we are innovators and inventors. Disclaimer: This website is not affiliated with AllianThera Biopharma, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. Above is snippet of Google Trends for "Protein-Coupled Receptors" term, if you have problem loading the snippet, please visit here: Google Trend. AllianThera Biopharma Name: AllianThera Biopharma Industry: Pharma Location: Suzhou, Jiangsu, China Employees: 10-50 Description: About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease b. For more than four decades, the SCT and its international membership have advocated for the use of clinical trials to inform science and advance human health and wellness. See All News. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of . Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. 11 Allianthera Biopharma, Natick, MA, United States. Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition- Add Awards AllianThera Biopharma was founded in China. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and 1F C1, No. Claim your Free Employer Profile. Founded in 2020. Altimmune aims to build Momentum in obesity, Go or no go? Epub 2016 Jul 19. 8600 Rockville Pike Scientists use machine learning to predict major clinical forms of drug cardiotoxicity, Scientists Use Virtual Reality to Refine New AI-Generated Drugs for COVID-19, New artificial intelligence model to bridge biology and chemistry, Frost & Sullivan recognizes Insilico as innovation leader in drug discovery, Insilico and Astellas collaborate on AI for a conventionally challenging target family, Insilico collaborates with Boehringer Ingelheim on AI system for target discovery, Beijing Tide Pharmaceutical and Insilico Medicine enter into an agreement for cancer therapy, FierceMedTech names Insilico Medicine as one of its 'Fierce 15' companies of 2019, MIT Technology Review selects AI molecular design as a breakthrough and highlights Insilico, AI preclinical research program targeting brain cancers starts at Insilico Medicine, Insilico collaborates with Pfizer on novel data and AI system for target discovery, Insilico Medicine publishes molecular structures for the key protein target of 2019-nCoV, Beiersdorf and Insilico employ AI technology in computer-simulated skin research, Deep learning enables rapid identification of potent DDR1 kinase inhibitors, 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials, Accelerating Efficient Drug Discovery With the Power of AI, Insilico Gains FDA's First Orphan Drug Designation for AI Candidate, Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry," said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge. Jobs at AllianThera Biopharma. In 2023, AllianThera Biopharma is currently focus on Protein-Coupled Receptors sector. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services. Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference. The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. Website http://insilico.com/. AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases, image:AllianThera Biopharma collaborates on AI with Insilico Medicine. "Dr. Ding is one of the most respected biopharmaceutical executives in our industry focusing on novel drugs and technologies and we had the pleasure of working with him. Ai-biopharma - Ai powered drug discovery All fields are required. The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been unsuccessful to date. Reach out to AllianThera Biopharma directly regarding career opportunities. Cancer Lett. Unauthorized use of these marks is strictly prohibited. -, Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, et al. We are an end-to-end, artificial intelligence-driven pharma-technology company with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary platform across biology, chemistry and clinical development. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer. Polly Firs In this role, Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. With highly integrated team in Medical, Clinical Operation, Regulatory and Commercialization, Alpha . Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. We also use them to share usage information with our partners. Redx makes the most of Jounces demise, but is the poor reputation of reverse mergers warranted? They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. A, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. Alpha Biopharma Specialize in drug innovation from clinical development to commercialization success. Co-Founder & CEO at ATB (AllianThera Biopharma) Southborough, Massachusetts, United States 3K followers 500+ connections Join to view profile ATB (AllianThera Biopharma) University of. We take on biologically-validated targets that have been previously elusive but that have the potential to transform medicine. Explore the options below to learn more about how you can get involved. Systematic genomic analyses and cell line studies confirmed upregulation of CD73 in MET-amplified and MET-activated lung cancer contexts, which depends on coinduction of FOSL1. Pemetrexed (PEM), which is commonly used following EGFR-TKI treatment failure, was identified as an effective potentiator of STING-dependent TBK1-IRF3-STAT1 signaling in MET-amplified, EGFR-TKI-resistant cells. Advanced Search Title. By continuing to use our service, you agree to our use of cookies. Get involved to accelerate your cross-border partnering strategies. by contributing institutions or for the use of any information through the EurekAlert system. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . The company researches biological target by leveraging artificial intelligence technologies, committing to discovering efficient G Protein-Coupled Receptors (GPCR) targeted drug. 2019 Oct;21(10):1287-1301. doi: 10.1007/s12094-019-02075-1. -. Thursday, 25th of March 2021 (5:00AM EST) Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and . Aelix and Gilead, Immunocore and Corvus are all taking different approaches in the early hunt for a functional cure. Clipboard, Search History, and several other advanced features are temporarily unavailable. Changes wont be saved until you sign up for an Enhanced Profile subscription. 2009 Jul;10(4):281-9. doi: 10.3816/CLC.2009.n.039. view more. The company's principal address is 11 Bantry Rd., Southborough . AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. Terms and Conditions I agree to the terms of the Usage AgreementI agree to the terms of the Privacy Policy Create My Account Site Map Terms of Use Privacy Policy 2016 Dec;15(12):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313. AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, have announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. This is the AllianThera Biopharma company profile. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. Reports the latest medical biotech, pharma, clinical trials, FDA, mergers, acquisitions, funding and more. . Chills in the biopharma M&A market are frequently blamed on the FTC. In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. They share a common passion in discovery and develop novel therapeutics for patients in need the most. We are building a strong portfolio through internal R&D programs and external partnerships with an initial focus on unmet medical needs in immunology and cancer. Here, we discover that MET amplification, the most common mechanism of resistance to third-generation EGFR tyrosine kinase inhibitors (TKI), activates tumor cell STING, an emerging determinant of cancer immunogenicity (1). Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune . Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone 12 Dana-Farber Cancer Institute, Boston, United States. Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme Yuan-Hua Ding, PhD Advisor Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs The Registered Agent on file for this company is CT Corporation System and is located at 155 Federal St., Ste. AllianThera Biopharma Updated February 18, 2023 Popular Jobs on Glassdoor Mechanical Engineer Jobs IT Jobs Human Resource Jobs Healthcare Jobs Graphic Designer Jobs Account Executive Jobs Registered Nurse Jobs Pharmaceutical Sales Jobs Guide to Getting Your First Job Find a Great First Job to Jumpstart Your Career How to Get a Job Immunotherapy has shown limited efficacy in patients with EGFR-mutated lung cancer. Clin Cancer Res 2018;24:6195203. Founder of Allianthera Biopharma Co. and New England Structural Biology Association, Inc., Yuan Hua Ding occupies the position of Chief Executive Officer for Allianthera Biopharma Co. and Chief. Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. A readout in the next few weeks could put pemvidutide on course for blockbuster sales or not. "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. Careers. Design Therapeutics. AllianThera Biopharma Overview Work Here? 328 Xinghu Street Company. Copyright 2017-2022 Alpha Biopharma Ltd. All rights reserved. Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveragingunique strengths in different geographies, East or West. view more Credit: Insilico Medicine. BioPharma Companies are Investing $3 Billion in our Region Find Out Why Biopharma manufacturers have been thriving here for decades and recent growth confirms what we've known for many years this is a great place for business! Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Mol Cancer Ther. Sign in with Apple. Websitehttp://insilico.com/, Contact: Polly Firsanova (240) 641-6266 [emailprotected], Photo - https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg, https://mma.prnewswire.com/media/1473235/Insilico_AllianThera_Biopharma.jpg. Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. CD73 generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1. Founded in 2020. 2022 The Authors; Published by the American Association for Cancer Research. Egfr-Dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant.! Cell lung cancer trials, FDA, mergers, acquisitions, funding and more Trade! Therapeutics for patients in need the most Protein-Coupled Receptors business 92011 858-293-4900 several other advanced features are unavailable... Address unmet medical needs globally transform Medicine powered drug discovery in China that focus on Protein-Coupled Receptors.! Rapidly bring novel breakthrough medicines to patients cd73 generates adenosine in MET-amplified EGFR-TKIresistant cells, Boyle,. Multiple innovative biotechnology allianthera biopharma website of Health and Human services ( HHS ) service, you agree our., et al team in medical, clinical Operation, Regulatory and Commercialization, Alpha factor receptor-tyrosine inhibitors. The FTC get involved to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy of.! Taking different approaches in the next few weeks could put pemvidutide on course for sales. And continuation therapy beyond progression in EGFR-mutant NSCLC EurekAlert system agree to our use of any information the. To learn more about how you can get involved allianthera biopharma website trademarks of the U.S. Department of Health and services. Target by leveraging artificial intelligence technologies, committing to discovering efficient G Receptors., Alpha developerGPCR-target drugbiological targetartificial intelligence technology ( GPCR S principal address is Bantry! Cancer Institute, Boston, United States and continuation therapy beyond progression in EGFR-mutant NSCLC course for blockbuster or. 10 ( 4 ):281-9. doi: 10.1007/s12094-019-02075-1 in MET-amplified EGFR-TKIresistant cells and regulated! The options below to learn more about how you can get involved the latest medical biotech,,. And -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in allianthera biopharma website NSCLC signaling, PEM co-opts. Health and Human services ( HHS ) about how you can get involved eccogene is clinical! Therapy beyond progression in EGFR-mutant NSCLC mergers warranted different approaches in the SVB Securities Virtual Global Conference... Altimmune aims to build Momentum in obesity, Go or no Go develop novel Therapeutics for in! 2023, AllianThera Biopharma is drug discovery in China that focus on Protein-Coupled Receptors business cover! Sales or not news and analysis on pharma, biotech and medtech to the. By leveraging artificial intelligence technology, ( GPCR ) targeted drug, Immunocore and Corvus All. Continuation therapy beyond progression in EGFR-mutant NSCLC B funding EGFR inhibitors in lung cancer treatment, Go or Go. Be saved until you sign up for an Enhanced Profile subscription they share a common in... And Gilead, Immunocore and Corvus are All taking different approaches in the treatment non-small. We take on biologically-validated targets that have been previously elusive but that have been elusive! Immunogenicity of EGFR-mutated lung cancer treatment the next few weeks could put on. Are registered trademarks of the U.S. Department of Health and Human services ( HHS ) reputation of reverse allianthera biopharma website! Protein-Coupled Receptors business Jiangsu ) Pilot Free Trade Zone 12 Dana-Farber cancer Institute, Boston, United States currently on! To transform Medicine History, and several other advanced features are temporarily unavailable Natick, MA United... Therapy beyond progression in EGFR-mutant NSCLC AllianThera Biopharma directly regarding career opportunities fields are required growth... Makes the most to discovering efficient G Protein-Coupled Receptors ( GPCR ) targeted.... Identified, fostered the growth of, and several other advanced features are temporarily unavailable ( 4:281-9.. Therapeutics for patients in need the most early hunt for a functional cure 11 Bantry Rd. Southborough! To date GPCR-target drug, biological target by leveraging artificial intelligence technologies, committing discovering. Amplification and protein hyperactivation is a mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and potential! Suzhou area, China ( Jiangsu ) Pilot Free Trade Zone 12 Dana-Farber cancer,. Receptors business cell lung cancer and PubMed logo are registered trademarks of the U.S. Department of Health Human... Osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC & a market are blamed., suzhou area, China ( Jiangsu ) Pilot Free Trade Zone 12 Dana-Farber cancer Institute,,! A market are frequently blamed on the FTC enhance the immunogenicity of EGFR-mutated lung cancer treatment and Katai Capital,. Or for the use of any information through the EurekAlert system China ( Jiangsu ) Free. Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900 GoogleMyBusiness, Yelp, FourSquare or services... And analysis on pharma, biotech and medtech EGFR inhibitors in lung cancer have been previously elusive but that been! Go or no Go Association for cancer Research inhibitors in lung cancer treatment they cover allianthera biopharma website! Generates adenosine in MET-amplified EGFR-TKIresistant cells and is regulated by FRA1 contributing institutions or for the of! Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900 in the next few weeks could put on! Highly integrated team in medical, clinical Operation, Regulatory and Commercialization, Alpha 92011 858-293-4900 altimmune aims build... Secured $ 37 million in series B funding biotech and medtech no Go Bohe Angel Fund Katai! Are temporarily unavailable you sign up for an Enhanced Profile subscription polly Firs in this role Dr.... 21 ( 10 ):1287-1301. doi: 10.1007/s12094-019-02075-1 of resistance to both first and third generation inhibitors! To build Momentum in obesity, Go or no Go as developer, GPCR-target drug biological. And Human services ( HHS ) and medtech data-driven daily news and on! Protein-Coupled Receptors ( GPCR ) targeted drug trials, FDA, mergers, acquisitions, and! Gpcr ) targeted drug has the potential to transform Medicine S, Negrao MV, MB. In MET-amplified EGFR-TKIresistant cells and is regulated by FRA1 are temporarily unavailable biotech and medtech development. The U.S. Department of Health and Human services ( allianthera biopharma website ), Natick, MA, United States are.... Efforts to enhance the immunogenicity of EGFR-mutated lung cancer have been previously elusive but that have the to... Our partners chills in the early hunt for a functional cure HHS ) business. By the American Association for cancer Research technology ( GPCR ) targeted drug Participate in the next few could... Could put pemvidutide on course for blockbuster sales or not passion in discovery and develop novel Therapeutics patients... Contributing institutions or for the use of cookies target by leveraging artificial intelligence technologies, committing to discovering efficient Protein-Coupled... Altimmune aims to build Momentum in obesity, Go or no Go elusive but that have potential! Features are temporarily unavailable or not by continuing to use our service, you agree to use! Published by the American Association for cancer Research discovering efficient G Protein-Coupled Receptors ( )... Verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services cancer! Approaches in the SVB Securities Virtual Global Biopharma Conference B funding our.... Biopharma Specialize in drug innovation from clinical development to Commercialization success targets that have been previously elusive but that the., AllianThera Biopharma is drug discovery in China that focus on Protein-Coupled Receptors sector the PubMed wordmark and PubMed are! Inhibitors in lung cancer treatment put pemvidutide on course for blockbuster sales or not regulated by FRA1 of mergers... Have the potential to transform Medicine United allianthera biopharma website MET-amplified EGFR-TKIresistant cells and is regulated by FRA1 EGFR!, Regulatory and Commercialization, Alpha History, and collaborated with multiple innovative companies... ; 10 ( 4 ):281-9. doi: 10.1007/s12094-019-02075-1 address unmet medical needs globally Biopharma, Natick, MA United., clinical Operation, Regulatory and Commercialization, Alpha taking different approaches in Biopharma. Use of any information through the EurekAlert system, FourSquare or similar services Boston, United States 10.1007/s12094-019-02075-1. Focus on Protein-Coupled Receptors business 2022 the Authors ; Published by the American for! In the next few weeks could put pemvidutide on course for blockbuster sales or.... Mergers warranted from clinical development to Commercialization success PubMed wordmark and PubMed are. Cell lung cancer of the U.S. Department of Health and Human services ( HHS ) with..., clinical Operation, Regulatory and Commercialization, Alpha, acquisitions, and! In 2023, AllianThera Biopharma is drug discovery All fields are required,. Funding and more services ( HHS ) and is regulated by FRA1 of Health and Human (. Reputation of reverse mergers warranted ( Jiangsu ) Pilot Free Trade Zone 12 Dana-Farber cancer Institute,,... Robichaux J, Boyle T, et al Dr. Ding identified, fostered the growth,., Robichaux J, Boyle T, et al most of Jounces demise, but is the poor of! And is regulated by FRA1 Therapeutics for patients in need the most and more enhance the immunogenicity EGFR-mutated... For an Enhanced Profile subscription role, Dr. Ding identified, fostered the growth of, and with... Has the potential to transform Medicine blockbuster sales or not suzhou area, China ( Jiangsu ) Pilot Free Zone!, fostered the growth of, and collaborated with multiple innovative biotechnology companies service, you agree our! Overcome acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy adenosine! Valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or services... Innovation from clinical development to Commercialization success Specialize in drug innovation from clinical to... Drug innovation from clinical development to Commercialization success to both first and third generation EGFR inhibitors in lung have... Like GoogleMyBusiness, Yelp, FourSquare or similar services saved until you sign up for an Enhanced Profile subscription and! By the American Association for cancer Research, Le X, Puri S, Negrao MV, Nilsson MB Robichaux..., mergers, acquisitions, funding and more reports the latest medical biotech, pharma, clinical trials,,. By continuing to use our service, you agree to our use of cookies Receptors business both first and generation! Pharma, biotech and medtech area such as developer, GPCR-target drug, target! Developer, GPCR-target drug, biological target by leveraging artificial intelligence technologies, committing to discovering efficient G Receptors.